Codexis (NASDAQ:CDXS) Cut to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Codexis (NASDAQ:CDXS) from "Hold" to "Sell," causing the stock to fall 2.5% to $1.56, significantly below its 12-month high. Despite beating quarterly earnings expectations with a smaller loss and higher revenue than anticipated, the biotechnology company remains unprofitable, with a negative net margin and projected full-year loss. Institutional investors and hedge funds hold a substantial 78.54% stake in the company.
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's earnings, which historically correlates strongly with stock price movement, making CDXS an attractive investment. The Zacks Rank system, based on earnings estimate revisions, has a strong track record of identifying stocks likely to outperform.
Codexis (CDXS) Stock Rallies On Longer Cash Runway Questions Remain
Codexis (CDXS) stock rallied 8.1% after its Q2 2026 earnings report, primarily due to management's revised expectation that its cash pile will fund operations through 2028, extending its cash runway. Despite this positive development, the company reported a US$12.0m net loss on US$14.9m in revenue, maintaining questions about its path to profitability and dilution risk. The market appears to be rewarding the extended runway more than near-term revenue softness, while bears point to ongoing losses and past dilution.
Codexis (CDXS) investor Laurence Lytton discloses 5.2% beneficial stake in shares
Laurence W. Lytton has reported a beneficial ownership of 5,592,972 shares of Codexis, Inc. (CDXS) common stock, which represents a 5.2% stake in the company. This disclosure was made via a SCHEDULE 13G/A filing with the SEC, indicating an increase in his holdings above the 5% threshold since June 30, 2026, due to subsequent purchases. Lytton exercises sole voting and dispositive power over the majority of these shares.
Codexis, Inc. Stock 12‑Month Price Target Cut to $6.5, Implies 339% Upside
The average 12-month price target for Codexis, Inc. (CDXS) stock has been slightly cut from $6.58 to $6.5 by 6 analysts, with forecasts ranging from $2 to $11. This updated target implies a significant potential upside of approximately 339% based on the August 11 closing price. Despite the slight target reduction, the consensus rating from 7 analysts remains "Buy," with 5 Buys and 2 Holds.
Codexis, Inc. Q2 2026 Earnings Call Summary
Codexis, Inc. reported a return to growth in its pharma biocatalysis business, driven by new product approvals and a significant label expansion. The company is strategically focusing on industrializing its ECOsynthesis platform to address projected siRNA demand, backed by recent equity financing and improved operational efficiency. Codexis anticipates strong second-half revenue, sustained high single-digit growth in biocatalysis, and is planning a new GMP manufacturing facility to support clinical trials and customer filings.
Codexis narrows Q2 loss, raises $25M to fund GMP expansion
Codexis Inc. (NASDAQ: CDXS) significantly narrowed its Q2 2026 net loss to $12.0 million and beat EPS estimates, though revenue slightly declined. The company also secured $25 million in equity financing, extending its cash runway until 2028 and enabling the expansion of its ECO GMP Manufacturing Center for siRNA production. These strategic moves and operational efficiencies position Codexis to advance its siRNA platform and expand manufacturing capabilities.
Codexis Reports Second Quarter 2026 Financial Results
Codexis, Inc. reported its second-quarter 2026 financial results, with total revenues of $14.9 million. The company reiterated its full-year 2026 financial guidance, projecting revenues between $72 million and $76 million. Key highlights include advancements in RNA therapeutic manufacturing, a successful equity capital raise of approximately $25 million, and plans to commence retrofit construction for its ECO GMP Manufacturing Center.
Codexis Inc (CDXS) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Codexis Inc (CDXS), highlighting its current earnings forecast score of 8.00 and an average price target of $7.00. Based on ratings from 7 analysts, the stock has a "Buy" trend with a significant upside space. The company's expected revenue for the next quarter is $14.35 million, and its EPS for the previous quarter was $0.11, with an expectation of -$0.14 for the next quarter.
Codexis (CDXS) Projected to Release Earnings on Tuesday
Codexis (CDXS) is anticipated to release its Q2 2026 earnings after the market closes on Tuesday, August 11th. Analysts project a loss of $0.17 per share on revenue of approximately $13.8 million. The biotechnology company previously beat expectations in Q1, reporting a $0.10-per-share loss against a $0.11 consensus estimate, and revenue of $15.25 million against $14.53 million expected.
Codexis, Inc. Revenue Breakdown – NASDAQ:CDXS
Codexis, Inc. (NASDAQ: CDXS) generated $70.39 million in revenue last year, primarily from its Biocatalysts, Pharmaceutical Intermediates, and Codex Biocatalyst Panels and Kits segment. This represented an increase from the $59.34 million reported the previous year. The United States was the largest contributor to revenue, accounting for $43.54 million.
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
Codexis, Inc. (Nasdaq: CDXS) has appointed Dr. David Butler to its Strategic Advisory Board, bringing over 20 years of experience in the oligonucleotide field, particularly in siRNA therapeutics manufacturing. Dr. Butler's expertise is expected to support Codexis' growth and innovation, while Carole Cobb is stepping down from the board. Codexis is a leading provider of enzymatic solutions for scalable therapeutics manufacturing.
Codexis Inc (CDXS) Financial Health: Profitability & Balance Sheet Analysis
Codexis Inc (CDXS) has a strong financial health score of 8.88, ranking 25th in its industry. The company reported a 102.15% year-over-year increase in its latest quarterly revenue and a 57.93% increase in net profit. However, several detailed financial metrics related to cash and cash equivalents, quality of earnings, operational efficiency, growth potential, and shareholder returns have not yet been disclosed by the company.
Press Release: Codexis Appoints David Butler, PhD, to Strategic Advisory Board
Codexis, Inc. has announced the appointment of Dr. David Butler to its Strategic Advisory Board. Dr. Butler brings extensive experience in pharmaceutical R&D, manufacturing, and supply chain management from his tenure at Amgen, which is expected to significantly contribute to Codexis's strategic initiatives in developing and commercializing enzymatic solutions. His expertise will be valuable as Codexis aims to advance its biocatalysis and enzyme engineering platforms.
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
Codexis, Inc. has appointed David Butler, PhD, to its Strategic Advisory Board to provide technical guidance, industry expertise, and strategic insight for the company's growth and innovation, particularly in the siRNA therapeutic sector. Dr. Butler brings over 20 years of experience in the oligonucleotide field, including roles at Hongene Biotech, Wave Life Sciences, Korro Bio, Alltrna, and Alnylam. This appointment aims to enhance Codexis's position in the industry as it industrializes its enzymatic technology for producing siRNA medicines.
Codexis appoints David Butler to strategic advisory board
Codexis, Inc. (NASDAQ:CDXS) has announced the appointment of David Butler to its Strategic Advisory Board. Butler brings over two decades of experience in the oligonucleotide field, having previously served as Chief Technology Officer at Hongene Biotech Corporation and in leadership roles at Wave Life Sciences, Korro Bio, and Alltrna. His expertise in siRNA therapeutics and manufacturing will be crucial as Codexis expands its market presence.
20-Year Oligonucleotide Veteran David Butler Joins Codexis Board
Codexis (Nasdaq: CDXS) has appointed Dr. David Butler, a veteran with over 20 years of experience in oligonucleotide therapeutics, to its Strategic Advisory Board. Dr. Butler will provide critical technical guidance and industry expertise to support Codexis' growth and innovation in complex oligonucleotide therapeutics manufacturing. Concurrently, Carole Cobb will be stepping down from the Strategic Advisory Board.
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
Codexis, Inc. has announced the appointment of Dr. David Butler to its Strategic Advisory Board to provide technical guidance and strategic insight, particularly in the siRNA therapeutic sector. Dr. Butler brings over 20 years of experience in the oligonucleotide field, having previously served as CTO at Hongene Biotech Corporation and held leadership roles at Wave Life Sciences, Korro Bio, and Alltrna. Concurrently, Carole Cobb is stepping down from the board, with Codexis acknowledging her valuable contributions.
Codexis appoints David Butler to strategic advisory board By Investing.com
Codexis, Inc. has appointed David Butler to its Strategic Advisory Board. Butler brings over 20 years of experience in the oligonucleotide field, having previously held key roles at Hongene Biotech Corporation, Wave Life Sciences, Korro Bio, Alltrna, and Alnylam. His expertise in siRNA therapeutic manufacturing and scale-up is expected to significantly benefit Codexis as it expands its industry presence.
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
Codexis, Inc. has appointed Dr. David Butler to its Strategic Advisory Board to provide technical guidance and industry expertise, particularly in the siRNA therapeutic sector. Dr. Butler brings over 20 years of experience in the oligonucleotide field, having previously held positions at Hongene Biotech, Wave Life Sciences, Korro Bio, Alltrna, and Alnylam. Concurrently, Carole Cobb has stepped down from the SAB, with Codexis acknowledging her significant contributions.
Codexis, Inc. Revenue Breakdown – BX:4QK
Codexis, Inc. (BX:4QK) generated 55.80 million CHF in revenue last year, primarily from its Biocatalysts, Pharmaceutical Intermediates, and Codex Biocatalyst Panels and Kits segment. This revenue marks an increase from 53.90 million CHF the previous year. The United States was the largest contributor to revenue, accounting for 34.51 million CHF.
Codexis Inc (CDXS) Institutional Confidence
The article analyzes the institutional confidence score for Codexis Inc (CDXS), noting its current score of 7.00, which ranks 80 out of 385 in the Biotechnology & Medical Research industry. It highlights that the institutional shareholding proportion is 73.00%, a 13.55% decrease quarter-over-quarter. Bill Nygren | OAKMX is identified as the largest institutional shareholder, despite significantly decreasing holdings.
Form 424B5 Codexis Inc For: 24 July By Investing.com
This article from Investing.com reports on a Form 424B5 filing by Codexis Inc on July 24th. The brief news item indicates that Codexis Inc's stock symbol is CDXS, which was down 2.00% at the time of publication. The page also features current market data for various indices, commodities, and shares, alongside popular news and trending stocks.
Codexis, Inc. (CDXS) investors report 7.3% stake in 7.85M shares
Telemark Asset Management, LLC, Telemark Fund, LP, and Colin S. McNay have jointly reported beneficial ownership of 7,846,411 shares of Codexis, Inc. (CDXS) common stock, representing a 7.3% stake. This ownership includes shared voting and dispositive power, calculating the percentage based on 107,561,409 outstanding shares as of July 24, 2026. The filing highlights key figures such as the number of shares owned and the ownership percentage, detailing the entities involved and their organizational structures.
Codexis to Report Second Quarter 2026 Financial Results on August 11
Codexis, Inc. announced it will release its second-quarter 2026 financial results on Tuesday, August 11, 2026, after market close. Management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the results and provide a business update. The webcast will be available on the Codexis Investor Relations website, and a telephone replay will be accessible for 48 hours.
Codexis to Report Second Quarter 2026 Financial Results on August 11
Codexis, Inc. (NASDAQ: CDXS) announced it will report its Q2 2026 financial results on Tuesday, August 11, 2026, after market close. The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss the results and provide a business update, which will be accessible via their Investor Relations website.
Codexis to Report Second Quarter 2026 Financial Results on August 11
Codexis, Inc. (NASDAQ: CDXS) announced it will report its second quarter 2026 financial results on Tuesday, August 11, 2026, after the market closes. The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss the results and provide a business update. The webcast will be available on the Codexis Investor Relations website.
Codexis schedules 4:30 p.m. ET webcast after Aug. 11 close
Codexis (NASDAQ: CDXS) announced it will report its Q2 2026 financial results on Tuesday, August 11, 2026, after the market closes. Management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss results and provide a business update, with access details provided for both live participation and a 48-hour replay. The company's previous earnings-date announcements have been followed by positive 24-hour stock reactions.
Codexis Inc (CDXS) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Codexis Inc (CDXS), rating its overall risk score at 2.99, which ranks it 167 out of 386 in the Biotechnology & Medical Research industry. The company's high beta of 2.50 suggests significant volatility, with the stock likely to outperform in rising markets but underperform notably in declining ones. Key metrics like maximum drawdown, volatility, and Sharpe ratio are detailed, highlighting both potential returns and substantial risks associated with CDXS.
Codexis Inc (CDXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Codexis Inc (CDXS), detailing its price momentum score, current support and resistance levels, and signals from various technical indicators and moving averages. While the stock's price momentum is 5.56, suggesting it's suitable for range-bound swing trading, most indicators and all moving averages signal "Sell." The analysis also includes FAQs about technical ratings and moving averages.
CDXS|Codexis Inc|Price:1.480|Chg%:-0.510
Codexis Inc. is a provider of enzymatic solutions, leveraging its CodeEvolver technology to develop high-performance enzymes for pharmaceutical manufacturing and RNA-based therapeutics. The company's stock, CDXS, is currently priced at $1.480, reflecting a significant drop. This article provides a detailed company profile, including financial data, key executives, and institutional shareholding information.
CDXS Stock Falls As Codexis Prices Dilutive Share Offering
Codexis Inc. (CDXS) shares fell significantly after the company announced a dilutive public offering of 16.7 million new shares at $1.50 each to raise about $23.1 million. The move is intended to fund working capital, R&D, and general corporate purposes, extending the company's financial runway despite its current negative profitability and cash burn. The stock's price has already adjusted downwards, with the $1.50 offering price becoming a key reference level for traders gauging market absorption of the new supply.
Codexis, Inc. Revenue Breakdown – TRADEGATE:4QK
Codexis, Inc. (TRADEGATE:4QK) generated €59.93 million in revenue last year, primarily from its Biocatalysts, Pharmaceutical Intermediates, and Codex Biocatalyst Panels and Kits segment. This represented an increase from €57.33 million the previous year. The majority of the revenue, €37.07 million, originated from the United States.
Codexis Market Sentiment
This article analyzes market sentiment for Codexis (CDXS) based on analyst consensus, short interest, options flow, and insider activity. Analysts have an "Overweight" consensus with an average price target significantly above the current stock price, while options flow indicates a bearish sentiment due to a high put/call ratio. Short interest is declining, which is considered bullish, but there has been no recent insider activity.
CDXS|Codexis Inc|Price:1.480|Chg%:-0.510
This article provides a detailed financial overview of Codexis Inc (CDXS), including its stock price, market capitalization, and historical financial statements. It highlights the company's latest earnings, revenue, and analyst ratings, alongside quarterly and annual data for EPS, revenue, net profit, margins, debt-to-assets ratio, and cash flow components. The report also includes FAQs offering quick answers to key financial metrics based on the FY2025 earnings report.
Codexis Announces Proposed Public Offering of Common Stock
Codexis, Inc. has commenced an underwritten public offering of shares of its common stock, with an option for underwriters to purchase an additional 15%. The company plans to use the net proceeds for working capital and general corporate purposes, including research, development, and business activities. Piper Sandler and Cantor are serving as joint bookrunning managers, with Craig-Hallum as co-manager for the offering.
Codexis Expects Offering to Close on or About July 27 >CDXS
Codexis anticipates the closing of its offering will occur on or about July 27. This brief announcement provides a definitive timeline for the completion of the company's offering under the stock symbol CDXS.
CDXS Stock Slides As Dilutive Offering Reshapes Trading Setup
Codexis Inc. (CDXS) shares have slid by over 22% following the announcement of an underwritten public offering of 16.7 million new common shares at $1.50 each, with an option for underwriters to purchase an additional 2.5 million shares. This dilutive offering, while extending the company's cash runway by providing $23.1 million in net proceeds for working capital and R&D, introduces near-term selling pressure as the market digests the new supply. The stock is now trading tightly around the offering price, presenting both dilution risk for existing holders and a classic post-offering setup for active traders.
Codexis Inc (CDXS) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Codexis Inc (CDXS), highlighting its current earnings forecast score of 8.00 and an average price target of $7.00. Based on 7 analysts, the stock has a "Buy" trend with a potential upside of +199.24%. Key financial forecasts include an expected revenue of $14.35M for the next quarter and an anticipated EPS of -$0.14.
Codexis prices 16,666,667-share common stock offering at $1.5 per share
Codexis has priced an underwritten public offering of 16,666,667 common shares at $1.5 each, expecting net proceeds of approximately $23.1 million. The closing is targeted for around July 27, 2026, with underwriters holding a 30-day option to purchase additional shares. The company plans to use the proceeds for working capital, general corporate purposes, research, development, and business activities.
Aberdeen Group plc Reduces Stake in Codexis Inc: A Strategic Por
Aberdeen Group plc has reduced its stake in Codexis Inc. by selling over 1.9 million shares, now accounting for 0.02% of its portfolio. This move is part of Aberdeen's broader strategy to optimize its $61.94 billion equity portfolio, focusing on high-growth sectors like technology and healthcare. Codexis, a biotechnology company specializing in enzyme-based solutions, faces financial challenges despite being modestly undervalued, with its stock price dropping 12.39% post-transaction.
Codexis Announces Proposed Public Offering of Common Stock
Codexis, Inc. has announced the commencement of an underwritten public offering of its common stock to fund working capital and general corporate purposes, including research and development. The company also intends to grant the underwriters a 30-day option to purchase additional shares. The offering is subject to market conditions, and a registration statement has been filed with the SEC.
Codexis Intends to Use Net Proceeds to Fund Working Capital, Other General Corporate Purposes >CDXS
Codexis, a company involved in protein engineering, announced its intention to use the net proceeds from its financial activities to fund working capital and other general corporate purposes. This strategic allocation of funds suggests a focus on operational stability and flexibility for future growth initiatives.
Codexis Prices 16.7 Million Shares at $1.50 in Public Stock Offering
Codexis, Inc. (MT Newswires) has priced a public offering of 16.7 million shares at $1.50 per share, resulting in a -24.37% change from its current price. This news was published at 03:55 am EDT on July 24, 2026. The company is actively involved in biotechnology and medical research, leveraging its CodeEvolver platform for enzyme development and RNA manufacturing.
Codexis Announces Pricing of Public Offering of Common Stock
Codexis, Inc. has announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at $1.50 per share, expecting to raise approximately $23.1 million in net proceeds. The company plans to use these funds for working capital and general corporate purposes, including research, development, and business activities. The offering is anticipated to close around July 27, 2026, with Piper Sandler and Cantor acting as joint bookrunning managers.
Codexis Announces Pricing of Public Offering of Common Stock
Codexis, Inc. has announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at $1.50 per share, expecting to raise approximately $23.1 million in net proceeds. The company plans to use these funds for working capital and general corporate purposes, including research, development, and business activities. The offering is expected to close around July 27, 2026, with Piper Sandler and Cantor acting as joint bookrunning managers.
CDXS Q2'26 Earnings: revenue estimate is 13.82M USD
Codexis, Inc. (CDXS) is scheduled to release its Q2'26 earnings on July 30, with an anticipated revenue estimate of $13.82 million USD and an EPS of ($0.14) USD. The article provides a table of past reported and estimated revenues and EPS, highlighting both the estimates for the upcoming quarter and previous surprises.
Top Penny Stocks To Watch In July 2026
This article identifies three penny stocks—Codexis (CDXS), BRC (BRCC), and Xtra-Gold Resources (XTGR.F)—that demonstrate financial strength and potential for growth despite being in the high-risk penny stock category. Codexis is leveraging its CodeEvolver platform for RNA therapeutics, BRC is expanding its coffee product sales, and Xtra-Gold Resources is a debt-free gold exploration company. The article provides an overview of each company's operations, financial health, and recent performance for investors seeking undervalued opportunities.
Aberdeen Group plc (CDXS) discloses 6.77M-share Codexis stake held via abrdn Inc.
Aberdeen Group plc and its subsidiary abrdn Inc. have reported beneficial ownership of 6,769,954 shares of Codexis, Inc. common stock, representing 7.45% of the class. They hold shared voting and shared dispositive power over these shares, which are managed by abrdn Inc. on behalf of underlying clients. Aberdeen Group plc is the parent company organized in the United Kingdom, while abrdn Inc. is organized in the United States.
Price to earnings forward of Codexis, Inc. – NASDAQ:CDXS
This article provides the "Price to earnings forward" metric for Codexis, Inc. (NASDAQ:CDXS). It is a brief financial data point for the company, accessible through TradingView. The content primarily focuses on the display of this specific financial metric.
